Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human AME Study of EDG-7500
NCT06738836Phase 1Completed
- Start
- Dec 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of edg-7500 in hypertrophic cardiomyopathy (HCM). Primary endpoints: Mass Balance (cumulative elimination of 14C-related material in urine and feces), Maximum Plasma Concentration (Cmax) of EDG-7500 and 14C Total Radioactivity and 3 more. Started Dec 2024; status: completed.
02
Drugs
edg-7500
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT06738836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06738836.